17-beta-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease

Am J Cardiol. 2005 Sep 1;96(5):664-7. doi: 10.1016/j.amjcard.2005.04.040.

Abstract

In this study we randomly compared the estradiol eluting stent (17-beta-E) with phosphorylcholine (PC)-coated stents in native coronary arteries. The incidence of angiographic restenosis was 23% in the 17-beta-E group and 31% in the PC group (p = 0.34). The major adverse cardiovascular event rates were also similar in the 2 groups (17% in the 17-beta-E group vs 22% in the PC group, p = 0.47). The mid-term clinical and angiographic outcomes did not indicate superiority of the 17-beta-E eluting stent over the control PC stent.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Angioplasty, Balloon, Coronary / instrumentation*
  • Coated Materials, Biocompatible*
  • Coronary Angiography
  • Coronary Disease / diagnostic imaging
  • Coronary Disease / therapy*
  • Coronary Restenosis / diagnostic imaging
  • Coronary Restenosis / epidemiology
  • Coronary Restenosis / prevention & control
  • Estradiol / therapeutic use*
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Phosphorylcholine / therapeutic use*
  • Retrospective Studies
  • Stents*
  • Treatment Outcome

Substances

  • Coated Materials, Biocompatible
  • Phosphorylcholine
  • Estradiol